4.0 Article

The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis

Journal

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Volume 39, Issue 1, Pages 38-41

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.3109/03009740903096101

Keywords

-

Categories

Ask authors/readers for more resources

Objectives: Ankylosing spondylitis (AS) is associated with an increased cardiovascular (CV) risk. Conduction disturbances (CD) may explain the CV burden, as they are independently associated with cardiac disease. The aim of this study was (1) to determine the prevalence of CD in AS, and (ii) to evaluate the relationship between CD and demographic and AS-related characteristics. Methods: A rheumatological evaluation assessing demographic and AS-related characteristics and a resting standard 12-lead electrocardiogram (ECG) were performed in 131 consecutive AS patients. Results: A first-degree atriciventricular (AV) block was found in six (4.6%) patients. One (0.8%) patient suffered from a complete right bundle branch block (RBBB) and one (0.8%) patient had a left anterior hemiblock. A prolonged QRS (pQRS) interval was observed in 38 (29.2%) patients, including those with a complete or incomplete BBB. Age, disease duration, and body mass index (BMI) were significantly associated with the PR interval, and male gender, disease duration, and the Bath Ankylosing Spondylitis Metrology Index (BASMI) with the QRS interval. In multivariate analyses, disease duration remained independently associated with both the PR and the QRS intervals. Conclusion: Intraventricular CD is highly prevalent in AS, particularly in patients with long-standing disease. Further research is needed to determine whether intraventricular CD contribute to the increased CV risk and long-term CV mortality in AS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Rheumatology

Elevated Fab glycosylation of anti-hinge antibodies

J. Koers, N. I. L. Derksen, W. J. J. Falkenburg, P. Ooijevaar-de Heer, M. T. Nurmohamed, G. J. Wolbink, T. Rispens

Summary: This study found that anti-hinge antibodies (AHAs) and elevated levels of Fab glycosylation are present not only in patients with rheumatoid arthritis (RA), but also in healthy controls (HCs). These results suggest that extensive Fab glycosylation may develop in response to an inflammatory proteolytic microenvironment, but is not restricted to RA.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Does a short course of etanercept influence disease progression and radiographic changes in patients suspected of non-radiographic axial spondyloarthritis? Three -years follow- up of a placebo-controlled trial

T. Rusman, M. A. C. van der Weijden, M. T. Nurmohamed, C. J. van Denderen, R. B. M. Landewe, P. M. Bet, C. M. A. van der Bijl, C. J. Van der Laken, I. E. van der Horst-Bruinsma

Summary: The study found that 16 weeks of etanercept treatment did not have an impact on disease activity, the chance of biological treatment, or radiographic progression in patients with suspected non-radiographic axial spondyloarthritis.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Prevalence and Radiographic Progression of Hip Involvement in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors

Maria Konsta, Michael T. Nurmohamed, Alexios Iliopoulos, Petros P. Sfikakis, J. Christiaan van Denderen, Ingrid Visman, Grigorios T. Sakelariou, Irene E. van der Horst-Bruinsma

Summary: The study aims to examine the prevalence of hip involvement in patients with ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) and estimate the effect of TNFi on radiographic progression of hip involvement compared to the spine. The results showed that approximately one-third of AS patients had hip involvement, which seemed to stabilize with TNFi treatment. There were no sex differences in the prevalence or progression of this manifestation.

JOURNAL OF RHEUMATOLOGY (2023)

Article Rheumatology

Long-term effectiveness and persistence of ustekinumab and TNF inhibitors in patients with psoriatic arthritis: final 3-year results from the PsABio real-world study

Laure Gossec, Stefan Siebert, Paul Bergmans, Kurt de Vlam, Elisa Gremese, Beatriz Joven-Ibanez, Tatiana Korotaeva, Frederic Lavie, Wim Noel, Michael T. Nurmohamed, Petros P. Sfikakis, Mohamed Sharaf, Elke Theander, Josef S. Smolen

Summary: This study evaluated the real-world persistence and effectiveness of the IL-12/23 inhibitor ustekinumab or a tumour necrosis factor inhibitor (TNFi) for psoriatic arthritis over 3 years. The results showed that the proportion of patients still on their initial treatments after 3 years was similar with ustekinumab and TNFi, but ustekinumab had a lower rate of adverse events.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Pharmacology & Pharmacy

Methotrexate Polyglutamates Exposure - Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate

Renske C. F. Hebing, Imke H. Bartelink, Helen R. Gosselt, Sandra G. Heil, Mauritis C. F. J. de Rotte, Pascal H. P. de Jong, Mike T. Nurmohamed, Robert de Jonge, Ron A. A. Mathot

Summary: This study investigated the association between red blood cell methotrexate polyglutamates (MTX-PG) concentrations and response in rheumatoid arthritis patients starting methotrexate (MTX) therapy. The results showed that there was an association between RBC-MTX-PG concentrations and Disease Activity Score in 28 joints (DAS28). Based on the findings, it is suggested to increase the dose if MTX-PG concentration is below 9.15 nmol/L at month 1, continue with the same dose if the concentration is above 47 nmol/L, and consider other treatment options if the concentration is above 78 nmol/L from 3 months onwards.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)

Article Pharmacology & Pharmacy

Sex differences in adverse drug reactions from Adalimumab and etanercept in patients with inflammatory rheumatic diseases

Helen R. R. Gosselt, Jette A. A. van Lint, Leanne J. J. Kosse, Phyllis I. I. Spuls, Harald E. E. Vonkeman, Sander W. W. Tas, Frank Hoentjen, Michael T. T. Nurmohamed, Bart J. F. van den Bemt, Martijn B. A. van Doorn, Naomi T. T. Jessurun

Summary: Sex differences exist in the frequency and nature of ADRs in patients with inflammatory rheumatic diseases, but not in ADR burden.

EXPERT OPINION ON DRUG SAFETY (2023)

Article Rheumatology

Clinical evaluation of optical spectral transmission imaging for detection of disease activity in rheumatoid arthritis

A. B. Blanken, M. Korteweg, L. van Boheemen, R. F. van Vollenhoven, M. T. Nurmohamed, C. J. van der Laken

Summary: The study aimed to investigate the performance and factors of influence of optical spectral transmission (OST) imaging as a new technique for measuring joint inflammation in rheumatoid arthritis (RA). The results showed significant differences in OST scores between RA patients and the control group, and moderate correlations between OST scores and ultrasound and clinical disease activity.

SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2023)

Review Rheumatology

Do Disease-Modifying Anti-rheumatic Drugs and Exercise Therapy Have a Combined Effect on Disease Activity in Patients with RA? A Scoping Review

M. Sobejana, M. van der Esch, J. van den Hoek, G. Kitas, M. van der Leeden, M. T. Nurmohamed, G. S. Metsios

Summary: In addition to DMARD treatment, exercise is increasingly promoted in patients with RA, but few studies have investigated the combined effects of these interventions on disease activity. This scoping review summarized the evidence on whether a combined effect can be detected in studies where exercise intervention was performed in addition to DMARD treatment. Eleven studies were included, and although some showed significant reductions in disease activity outcomes for the exercise + medication group compared with the medication-only group, most studies had weak methodological quality.

CURRENT RHEUMATOLOGY REPORTS (2023)

Article Rheumatology

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Mikkel Ostergaard, Ronald F. van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C. Nordstrom, Michael T. Nurmohamed, Bjorn Gudbjornsson, Lykke Midtboll Ornbjerg, Pernille Boyesen, Kristina Lend, Kim Horslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur Grondal, Simon Krabbe, Joakim Lindqvist, Inger Gjertsson, Daniel Glinatsi, Meliha Crnkic Kapetanovic, Anna-Birgitte Aga, Francesca Faustini, Pinja Parmanne, Tove Lorenzen, Cagnotto Giovanni, Johan Back, Oliver Hendricks, Daisy Vedder, Tuomas Rannio, Emma Grenholm, Maud Kristine Ljosa, Eli Brodin, Hanne Lindegaard, Annika Soderbergh, Milad Rizk, Alf Kastbom, Per Larsson, Line Uhrenholt, Soren Andreas Just, David J. Stevens, Trine Bay Laurbjerg, Gunnstein Bakland, Inge Christoffer Olsen, Espen A. Haavardsholm, Jon Lampa, NORD-STAR Study Grp

Summary: This study compared the clinical and radiographic outcomes of different biological treatments with active conventional therapy in patients with early rheumatoid arthritis (RA). The results showed that abatacept and certolizumab pegol had higher clinical remission rates compared to active conventional therapy, while tocilizumab did not show significant differences. Radiographic progression was low and similar across treatments.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Rheumatology

Patient perspective on exercise intervention in rheumatoid arthritis with high risk of cardiovascular disease: a pilot qualitative study

J. van den Hoek, M. Sobejana, F. van Nes, G. Metsios, G. Kitas, M. van der Leeden, M. T. Nurmohamed, M. van der Esch

Summary: The objective of this study was to gain insight into the perceptions and experiences of patients with rheumatoid arthritis and a high cardiovascular disease risk (CVD-RA) undergoing an exercise intervention. The study analyzed data from six patients through face-to-face interviews and identified seven themes related to perceptions and experiences. The findings highlighted the importance of being viewed as a person and feeling safe.

RHEUMATOLOGY INTERNATIONAL (2023)

Article Rheumatology

Predictors for response to electronic patient-reported outcomes in routine care in patients with rheumatoid arthritis: a retrospective cohort study

Jimmy Wiegel, Bart F. Seppen, Michael T. Nurmohamed, Marieke M. ter Wee, Wouter H. Bos

Summary: Routine collection of ePROs prior to consultations can improve clinical care, but a low response rate may limit its benefits. This study found that patients between 55 and 73 years of age and with higher socio-economic status were more likely to complete the ePROs, while patients living in urban areas had lower odds.

RHEUMATOLOGY INTERNATIONAL (2023)

Article Rheumatology

Facilitators and barriers to adhere to monitoring disease activity with ePROs: a focus group study in patients with inflammatory arthritis

Bart F. F. Seppen, Jimmy Wiegel, Michael T. T. Nurmohamed, Wouter H. H. Bos, Marieke M. M. ter Wee

Summary: Telemonitoring disease activity with ePROs can reduce rheumatic care workload by cutting down on outpatient clinic visits, but low adherence to reporting ePROs is common. This study aimed to identify facilitators and barriers to weekly monitoring of disease activity. Focus group discussions were held with patients who had recently participated in telemonitoring studies using a smartphone app for ePRO completion. Thematic analysis revealed five themes related to adherence: questionnaire frequency, discussing results, physical consultations, patient insight, and user experience. Both barriers and facilitators were found within these themes. The results suggest that maximizing the perceived benefits of completing ePROs and tailoring their frequency based on patients' disease activity or preference, along with training clinicians to discuss the completed ePROs, may improve adherence.

RHEUMATOLOGY INTERNATIONAL (2023)

Article Rheumatology

Cardiovascular disease risk in patients with inflammatory arthritis nowadays still substantially elevated

Reinder Raadsen, Romy Hansildaar, Lianne C. Pouw, Femke Hooijberg, Laura Boekel, Gerrit Jan Wolbink, Arno W. R. van Kuijk, Michael T. Nurmohamed

Summary: This study evaluates the cardiovascular disease risk and prevalence of risk factors in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (SpA). The results show that the traditional cardiovascular risk factors are significantly elevated in these patients compared to healthy controls. However, after adjusting for traditional risk factors, the cardiovascular risk was not increased in these patients.

RMD OPEN (2023)

No Data Available